Phillip Md Et Al Frost Purchases 500,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 500,000 shares of the stock in a transaction on Wednesday, January 15th. The shares were acquired at an average cost of $1.48 per share, for a total transaction of $740,000.00. Following the transaction, the chief executive officer now owns 213,036,477 shares of the company’s stock, valued at approximately $315,293,985.96. The trade was a 0.24 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, January 17th, Phillip Md Et Al Frost bought 150,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.47 per share, with a total value of $220,500.00.
• On Friday, December 13th, Phillip Md Et Al Frost purchased 125,000 shares of OPKO Health stock. The stock was acquired at an average price of $1.59 per share, for a total transaction of $198,750.00.
• On Wednesday, December 11th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The shares were bought at an average cost of $1.56 per share, with a total value of $780,000.00.
• On Friday, November 29th, Phillip Md Et Al Frost acquired 199,072 shares of OPKO Health stock. The stock was bought at an average cost of $1.53 per share, for a total transaction of $304,580.16.
• On Friday, November 22nd, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The shares were bought at an average cost of $1.59 per share, with a total value of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The stock was bought at an average cost of $1.62 per share, for a total transaction of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost acquired 280,183 shares of OPKO Health stock. The shares were purchased at an average price of $1.50 per share, with a total value of $420,274.50.

OPKO Health Stock Performance

Shares of NASDAQ:OPK opened at $1.47 on Friday. The business’s 50 day simple moving average is $1.54 and its 200 day simple moving average is $1.51. OPKO Health, Inc. has a 1 year low of $0.86 and a 1 year high of $1.76. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The company has a market capitalization of $1.00 billion, a P/E ratio of -7.74 and a beta of 1.63.

Wall Street Analysts Forecast Growth

OPK has been the subject of several research reports. HC Wainwright reissued a “buy” rating and set a $3.00 price target on shares of OPKO Health in a report on Wednesday, January 8th. StockNews.com downgraded OPKO Health from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, Barrington Research restated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a research note on Friday, November 8th.

Institutional Trading of OPKO Health

Several large investors have recently modified their holdings of the stock. Rubric Capital Management LP raised its position in shares of OPKO Health by 800.0% in the 2nd quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company’s stock valued at $55,528,000 after buying an additional 39,486,490 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in OPKO Health by 142.5% in the third quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock valued at $2,227,000 after acquiring an additional 876,272 shares during the last quarter. Clearline Capital LP bought a new position in OPKO Health in the third quarter valued at approximately $1,083,000. Squarepoint Ops LLC acquired a new position in OPKO Health during the second quarter valued at approximately $592,000. Finally, Barclays PLC lifted its stake in OPKO Health by 154.5% during the third quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock worth $810,000 after purchasing an additional 329,870 shares during the last quarter. 64.63% of the stock is owned by institutional investors and hedge funds.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.